# Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia

> **NCT01193283** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 22 (actual)

## Conditions studied

- Aplastic Anemia
- Neutropenia
- Pancytopenia
- Severe Aplastic Anemia

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Cyclosporine

## Key facts

- **NCT ID:** NCT01193283
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01193283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01193283, "Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT01193283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*